Article Text

Download PDFPDF
Emerging transcatheter therapies for aortic and mitral disease
  1. A Messori,
  2. S Trippoli
  1. Careggi Hospital, Laboratorio di Farmacoeconomia, Florence, Italy
  1. Correspondence to Dr Andrea Messori, Careggi Hospital, Laboratorio di Farmacoeconomia, Florence, Italy; andreamessori{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the editor: One issue that has not been discussed in the paper by Christofferson et al1 is the cost-effectiveness of transcatheter therapies, particularly those based on the new transcatheter aortic valves.

Previous cost-effectiveness studies on surgical aortic valve replacement (AVR) compared AVR with best medical therapy (or no operation) and found that AVR had an acceptable cost-effectiveness profile (cost per quality-adjusted life year gained  =  approximately $13 500 calculated from an incremental lifetime cost of around $110 000 per patient and an incremental lifetime benefit of 8.2 quality-adjusted life years gained per patient in a series of 4617 subjects2). Likewise, …

View Full Text


  • Competing interests None.

  • Provenance and Peer review Not commissioned; not externally peer reviewed.